You are here: Industry Insights > Pharma in China

News List

Increasing production volume of the equipment in the context of centralized procurement Pintai/PharmaSources
November 23, 2023
How is the progress of China’s domestically produced PD-(L)1 “going global”? Yefenghong/PharmaSources
November 23, 2023
Recently, Coherus BioSciences announced that the FDA has approved the launch of PD-1 antibody toripalimab (marketed jointly by Junshi Biosciences and Coherus) for use in combination with gemcitabine/cisplatin as a first-line treatment for advanced recurre
What is MAH policy in China? ChatGPT/PharmaSources
November 09, 2023
In China, the Marketing Authorization Holder (MAH) system refers to a policy shift in the regulation of pharmaceutical products.
Suggesting on the best practice of becoming MAH of a drug in China ChatGTP/PharmaSources
November 09, 2023
Becoming a Marketing Authorization Holder (MAH) for a drug in China involves navigating a complex regulatory landscape.
How to register a drug into the market in China? ChatGPT/PharmaSources
November 08, 2023
Registering a drug for market approval in China involves a comprehensive and multi-step process that requires adherence to the country's regulatory requirements.
What are the new developments of the CNS drug R&D? ChatGPT/PharmaSources
November 08, 2023
The research and development of Central Nervous System (CNS) drugs have been the focus of ongoing advancements and innovations.
What is CNS disease? ChatGPT/PharmaSources
November 08, 2023
Central Nervous System (CNS) disease refers to a broad category of medical conditions that affect the brain and spinal cord, which together comprise the central nervous system.
A comprehensive review of the currently marketed ADC drugs: the industry maintains high prosperity WND
November 07, 2023
Antibody-drug conjugates (ADCs) are a class of drugs composed of antibodies targeting tumor antigens and a variable number of small molecule toxins linked through connectors.
Development Progress of Bispecific Antibodies in China Yefenghong/PharmaSources
November 07, 2023
Approved Bispecific Antibody Products Worldwide, New progress in the field of bispecific antibodies.
Research Progress on Platelet Membrane Biomimetic Drug Delivery Systems Xiaomichong/PharmaSources
November 02, 2023
Currently, in the research of nanoscale drug delivery systems, there are several problems such as poor biocompatibility, short blood circulation lifespan, insufficient active targeting, and low permeability through biological membranes.